• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Nanoscope Therapeutics Announces the Appointment of Samuel Barone, MD, as Chief Medical Officer

News
Article

Barone is a former FDA officer.

Samuel Barone, MD, joins Nanoscope Therapeutics Inc. as chief medical officer.

Nanoscope Therapeutics announced the appointment in a press release. Barone comes to Nanoscope from Gemini Therapeutics, where he served as chief medical officer.

"We are thrilled to welcome Dr. Barone to the Nanoscope team. The regulatory expertise garnered during his tenure at the FDA will be instrumental as we continue to advance our pipeline through late-stage clinical development and navigate the regulatory process," said Sulagna Bhattacharya, co-founder and CEO of Nanoscope. "Dr. Barone will support our mission to bring sight-restoring therapies to patients with inherited retinal diseases in an expeditious manner."

"Nanoscope has the potential to impact the treatment landscape with its gene-agnostic, sight-restoring optogenetic therapies and bring these transformative therapeutic options to patients with severe vision loss due to inherited retinal diseases, for which there are no restorative therapies available," said Dr. Barone. "I look forward to taking MCO-010 through approval and advancing Nanoscope's follow-on assets to the clinic."

Barone is a board-certified ophthalmologist and vitreoretinal surgeon. He also has experience with clinical development.

Related Videos
Related Content